文献速递甲状腺疾病

左甲状腺素新剂型治疗甲状腺功能减退:技巧还是陷阱?

New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?
PubMed 文献 · Thyroid · 2020-11-02

本文综述左甲状腺素(LT4)软胶囊和液体制剂与 traditional 片剂在甲减治疗中的证据。健康志愿者药代动力学研究显示生物等效,但临床治疗等效性在不同场景有差异;新剂型可能减少与食物、饮料和药物同服的限制,但支持其临床优势的证据较弱,需进一步研究。

要点

  • LT4软胶囊和液体剂型在健康志愿者中与片剂生物等效,但治疗等效性在临床场景有差异。
  • 新剂型可能减轻与食物、饮料和某些药物同服的严格限制,但证据较弱。
  • 胃酸分泌受损患者中新剂型是否优于片剂尚不明确。

核心结论

  • 支持LT4软胶囊和液体剂型在临床实践中优于传统片剂的证据较弱,推定的药代动力学机制不明确。

研究设计与样本

  • 综述文献,总结LT4新剂型(软胶囊和液体)与片剂比较的药代动力学和临床研究证据。

主要发现

  • 健康志愿者药代动力学研究中LT4软胶囊和液体剂型与片剂生物等效。
  • 新剂型的治疗等效性在多个临床场景中似乎不同。
  • 有证据提示新剂型可能减轻与食物、饮料和某些药物同服的严格限制。
  • 胃酸分泌受损患者中新剂型是否比片剂更好控制甲减仍不清楚。

关键数值与推荐

  • LT4药物使用率高达成年人群的5.3%。

临床怎么用

  • 新剂型主要适用于疾病波动和间歇使用干扰药物的特定患者,可能减少频繁剂量调整和就诊。

局限性

  • 支持新剂型临床优势的证据较弱,药代动力学机制不清楚,需进一步研究其获益、成本效益和机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Levothyroxine (LT4) as a medication is used by up to 5.3% of the adult population. For optimal efficacy, the traditional tablet formulation (LT4tab) requires that patients avoid concomitant ingestion with food, drinks, and certain medications, as well as excellent patient compliance. Some comorbidities influence bioavailability of LT4 and may mandate repeated dose adjustments. Summary: New LT4 formulations (soft gel [LT4soft] and liquid [LT4liq]) containing predissolved LT4 are claimed to improve bioavailability, presumably by facilitating absorption. Thus, these formulations may well be more suitable than LT4tab for patients whose daily requirements are subjected to variations in bioavailability. Here, we review the evidence and indications for use of new LT4 formulations and highlight areas of uncertainty that are worthy of further investigation. While bioequivalence is established for LT4soft and LT4liq administered to healthy volunteers compared with LT4tab in pharmacokinetic (PK) studies, therapeutic equivalence of the new formulations seems to be different in several clinical settings. Some evidence suggests that new formulations of LT4 may mitigate against the strict requirements relating to concomitant ingestion with food, drinks, and certain medications, which apply to traditional LT4 tablets. The principal indication is in selected patients with disease fluctuations and intermittent therapies with interfering medications, where the need for frequent dose adjustments and office visits may be diminished. Whether the use of LT4soft or LT4liq in patients with impaired gastric acid secretion results in better control of hypothyroidism than LT4tab remains unclear. Conclusions: The evidence in favor of using LT4soft and LT4liq in clinical practice over LT4tab is weak, and the underlying putative PK mechanisms unclear. Additional studies to investigate these potential benefits, define the cost-effectiveness, and understand the PK mechanisms involved with new LT4 formulations are needed.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nagy EV, Perros P, Papini E, et al. New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat? Thyroid. 2020. PMID: 33003978. doi:10.1089/thy.2020.0515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。